Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

(2021) Nicole Doria-Rose et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

(2021) Deborah Steensels et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

(2021) Mark W. Tenforde et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021

(2021) Kristina L. Bajema et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

(2021) Wesley H. Self et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Adapting the Surveillance Platform for Enteric and Respiratory Infectious Organisms at United States Veterans Affairs Medical Centers (SUPERNOVA) for COVID-19 Among Hospitalized Adults: Surveillance Protocol

(2021) Elissa Meites et al.   Frontiers in Public Health

The test-negative design for estimating influenza vaccine effectiveness

(2013) Michael L. Jackson et al.   VACCINE